Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.
A large number of unwanted adverse events and symptoms reported by patients in clinical trials are not caused by the drug provided, since most of adverse events also occur in corresponding placebo groups. These nocebo effects also play a major role in drug discontinuation in clinical practice, negat...
المؤلفون الرئيسيون: | Laura Wendt, Antje Albring, Sven Benson, Harald Engler, Andrea Engler, Anke Hinney, Winfried Rief, Oliver Witzke, Manfred Schedlowski |
---|---|
التنسيق: | مقال |
اللغة: | English |
منشور في: |
Public Library of Science (PLoS)
2014-01-01
|
سلاسل: | PLoS ONE |
الوصول للمادة أونلاين: | http://europepmc.org/articles/PMC4164653?pdf=render |
مواد مشابهة
-
Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond.
حسب: Tunbridge, E, وآخرون
منشور في: (2006) -
VAL158MET catechol O-methyltransferase polymorphism contributes to the development of preeclampsia
حسب: Tamara Sljivancanin Jakovljevic, وآخرون
منشور في: (2020-10-01) -
Subjective reward processing and catechol-O- methyltransferase Val158Met polymorphism as potential research domain criteria in addiction: A pilot study
حسب: Nico Rohlfing, وآخرون
منشور في: (2022-10-01) -
Human plasma homocysteine levels are associated with the catechol-O-methyltransferase Val158Met polymorphism
حسب: Tunbridge, E, وآخرون
منشور في: (2007) -
Association between the Catechol O-methyltransferase (COMT) Val158met polymorphism and different dimensions of impulsivity.
حسب: Leandro Fernandes Malloy-Diniz, وآخرون
منشور في: (2013-01-01)